Andrew Redfern
Overview
Explore the profile of Andrew Redfern including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
69
Citations
712
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jarrett S, Redfern A, Li J, Gutierrez C, Patel P, Akinola O, et al.
Int J Emerg Med
. 2025 Jan;
18(1):15.
PMID: 39819298
Background: Globally, most children seek emergency care at general rather than specialized pediatric emergency departments. There remains significant variation in the provision of pediatric emergency care, particularly in resource-constrained settings....
2.
Martin H, Saunders C, Redfern A, Hickey M
Clin Breast Cancer
. 2024 Oct;
24(8):e731-e736.
PMID: 39395849
Purpose: To examine utilization of a dedicated menopause symptoms after cancer clinic (MSAC) and to determine whether women referred to the MSAC for management of severe hot flush symptoms are...
3.
Lotan Y, Krishna V, Abuzeid W, Launer B, Chang S, Krishna V, et al.
J Urol
. 2024 Oct;
213(2):192-204.
PMID: 39383345
Purpose: There are few markers to identify those likely to recur or progress after treatment with intravesical bacillus Calmette-Guérin (BCG). We developed and validated artificial intelligence (AI)-based histologic assays that...
4.
Azad A, Bressel M, Tan H, Voskoboynik M, Suder A, Weickhardt A, et al.
Lancet Oncol
. 2024 Sep;
25(10):1267-1276.
PMID: 39293461
Background: Lutetium-177 [Lu]Lu-prostate-specific membrane antigen (PSMA)-617 improves survival and quality of life in patients with metastatic castration-resistant prostate cancer, but whether it confers a benefit in hormone-sensitive disease is unknown....
5.
Oh E, Redfern A, Hayne D
Expert Rev Anticancer Ther
. 2024 Sep;
24(11):1101-1115.
PMID: 39290171
Introduction: Urothelial carcinoma is a common malignancy affecting the urinary system, with the spectrum of disease encompassing non-muscle invasive, muscle-invasive and metastatic disease. On a background of almost half a...
6.
Oey O, Wijaya W, Redfern A
World J Exp Med
. 2024 Jul;
14(2):92558.
PMID: 38948420
Eribulin is a non-taxane synthetic analogue approved in many countries as third-line treatment for the treatment of patients with metastatic breast cancer. In addition to its mitotic property, eribulin has...
7.
Ilhan E, Jola L, van der Zalm M, Bernstein M, Goussard P, Redfern A, et al.
JMIR Hum Factors
. 2024 Jun;
11:e54983.
PMID: 38825834
Background: Pulse oximeters noninvasively measure blood oxygen levels, but these devices have rarely been designed for low-resource settings and are inconsistently available at outpatient clinics. Objective: The Phefumla project aims...
8.
Al-Zubaidi M, Ong K, Viswambaram P, Bangash H, Boardman G, McCombie S, et al.
BJUI Compass
. 2024 Apr;
5(4):473-479.
PMID: 38633828
Objectives: We aim to assess the clinical value of F-fluorodeoxyglucose positron (F-FDG-PET) scan in detecting nodal and distant metastasis compared with computed tomography (CT) scan in patients with urothelial carcinoma...
9.
Anthony M, Hoddinott G, Van Niekerk M, Dewandel I, McKenzie C, Bekker C, et al.
PLOS Glob Public Health
. 2024 Mar;
4(3):e0003020.
PMID: 38547177
The COVID-19 pandemic impacted families globally, directly and indirectly. Children presenting with respiratory illnesses are affected by emerging health systems and socioeconomic changes in the COVID-19 era. We explored the...
10.
Martin H, Redfern A
Cancer Med
. 2024 Jan;
13(1):e6846.
PMID: 38186326
Purpose: Aromatase inhibitors (AIs) are associated with reduction in bone mineral density (BMD). The use of bone strengthening agents zoledronic acid and denosumab are associated with improved breast cancer outcomes...